Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. It is an oral, selective ACTH antagonist.
Atumelnant is now in Phase 2 of development and you can read the latest research results at the link below:
Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results From a12-Week, Phase 2, Open-Label Study
Richard J. Auchus, MD, PhD, Peter J. Trainer, MD, Kathryn Jean Lucas, MD3, et al
Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024
Click here to read more about Alumelnant on Crinetics’ website.
Recent Blog Posts
A selection of articles from around the world in 2025
Here’s a selection of three articles from around the world in 2025 about CAH. They cover treatment methods and long term outcomes for people with CAH - making for interesting reading for anyone interested in or affected by CAH. These articles are not a recommendation...
COVID-19 Information & Guidance
As new guidance and information becomes available, we will do our best to link to it below - please check here for updates. If you contract COVID-19, remember to adhere to sick-day rules. Always seek guidance from your GP, endocrinologist or other appropriate medical...
Annual General Meeting – 2nd November, 3pm UK time in Oxford
The CAH Support Group is pleased to announce its 7th Annual General Meeting (AGM). It will be held in person at The Lighthouse, Oxford on Sunday 2nd November 2025 at 3pm UK time. A virtual Teams link is available on request. If you'd like to see the agenda and/or...